We found that these results are well aligned with recent publications, suggesting that increased expression of CD63 in certain cancer is correlated with increased activity of pro-tumorigenic cell signaling pathways, such as activation of β-catenin, phosphoinositide 3-kinases (PI3K), and extracellular signal-regulated kinases (ERK) [5]. The gene discussed is CD63; the disease is cancer.